TABLE 2.
Lipid changes from baseline to follow‐up on linear scale (in mmol/L)
| Drug | Lipid parameter | Treatment duration | Mean baseline | Change, mmol/L |
95% CI LL |
95% CI UL |
|---|---|---|---|---|---|---|
| Corticosteroids | Total cholesterol | Induction | 4.27 | 1.25 | 0.31 | 2.39 |
| Maintenance | 3.56 | 1.29 | 0.40 | 2.38 | ||
| HDL‐c | Induction | — | — | — | — | |
| Maintenance | — | — | — | — | ||
| LDL‐c | Induction | — | — | — | — | |
| Maintenance | — | — | — | — | ||
| Triglycerides | Induction | 1.16 | 0.08 | −0.13 | 0.34 | |
| Maintenance | — | — | — | — | ||
| Anti‐TNFα agents | Total cholesterol | Induction | 4.65 | −0.12 | −0.41 | 0.20 |
| Maintenance | 4.64 | 0.08 | −0.14 | 0.32 | ||
| HDL‐c | Induction | — | — | — | — | |
| Maintenance | 1.30 | 0.02 | −0.05 | 0.10 | ||
| LDL‐c | Induction | — | — | — | — | |
| Maintenance | 2.57 | −0.02 | −0.17 | 0.13 | ||
| Triglycerides | Induction | — | — | — | — | |
| Maintenance | 0.91 | −0.02 | −0.09 | 0.05 | ||
| Tofacitinib | Total cholesterol | Induction | 4.62 | 0.65 | 0.47 | 0.84 |
| Maintenance | 4.60 | 0.55 | 0.43 | 0.68 | ||
| HDL‐c | Induction | 1.42 | 0.24 | 0.15 | 0.34 | |
| Maintenance | 1.49 | 0.18 | 0.15 | 0.22 | ||
| LDL‐c | Induction | 2.56 | 0.35 | 0.21 | 0.48 | |
| Maintenance | 2.60 | 0.42 | 0.26 | 0.60 | ||
| Triglycerides | Induction | 1.14 | −0.01 | −0.01 | −0.04 | |
| Maintenance | 1.13 | −0.06 | −0.11 | −0.01 |
Abbreviations: LL, lower limit; UL, upper limit.